ReviewRadiologie (Heidelberg, Germany)2026
[MRI in neurodegenerative Parkinsonian syndromes].
Review in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) and atypical Parkinsonian syndromes (APS), including multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), are increasing worldwide. Early differential diagnosis is challenging due to overlapping symptoms and the often delayed appearance of pathognomonic signs.
objectivePresentation of the role of structural magnetic resonance imaging (MRI) in the differential diagnosis of neurodegenerative Parkinsonian syndromes. MATERIAL AND
methodsLiterature review of current guidelines and studies on T1-weighted and T2-weighted sequences, susceptibility-weighted imaging (SWI), diffusion-weighted imaging, volumetry and multiparametric approaches. The focus was on disease-specific atrophy patterns, quantitative methods and automated analyses.
resultsStructural changes in PD are usually subtle; the nigrosome‑1 (swallowtail) sign on SWI can provide diagnostic clues. The PSP shows pronounced midbrain atrophy, MSA demonstrates putaminal, pontine and cerebellar atrophy and CBD exhibits asymmetric cortical atrophy. Volumetric and multiparametric analyses increase the diagnostic accuracy, especially in early disease stages, although widespread clinical implementation remains limited.
conclusionStructural MRI provides early indicators of APS and aids the differential diagnosis. Quantitative and multiparametric methods improve objectivity and sensitivity, particularly for subtle or rare syndromes and could play an increasingly more important role in clinical practice.
Indexed as
Identifiers
41758332What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.